What is the clinical evidence from this study?

Population: Heart failure (HF) with secondary pulmonary hypertension (n=14). Intervention: T-1032 (Phosphodiesterase type 5 inhibitor) vs. Placebo. Primary outcome: Plasma levels of ANP, cGMP, and hemodynamic parameters.

What does this research mean for the field?

Long-term treatment with a PDE5 inhibitor improves pulmonary hypertension secondary to heart failure by enhancing the natriuretic peptides-cGMP pathway. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

October 25, 2004Journal of Cardiovascular Pharmacology

Long-Term Treatment with a Phosphodiesterase Type 5 Inhibitor Improves Pulmonary Hypertension Secondary to Heart Failure through Enhancing the Natriuretic Peptides-cGMP Pathway

View Full Paper

Ask AI

Bookmark

Key result

Oral PDE5 inhibitor T-1032 boosts plasma cGMP and improves hemodynamics in canine heart failure.

n=14

PICO

Population

14 dogs with heart failure induced by rapid pacing, followed for 2 weeks of treatment.

Intervention / Comparator

T-1032 (Phosphodiesterase type 5 inhibitor) vs Placebo (1 mg/kg; twice a day)

Primary Outcome

Plasma levels of ANP, cGMP, and hemodynamic parameters

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Does not support clinical use; leaves open translation of oral PDE5 inhibition benefits to human heart failure.

Cite This Study

Yamamoto et al. (2004) studied Heart failure (HF) with secondary pulmonary hypertension (n=14). T-1032 (Phosphodiesterase type 5 inhibitor) vs. Placebo was evaluated on Plasma levels of ANP, cGMP, and hemodynamic parameters. Oral administration of the PDE5 inhibitor T-1032 significantly increased plasma cGMP levels and improved cardiopulmonary hemodynamics in a canine model of heart failure.

synapsesocial.com/papers/6ac6fd69eed46391217cbfba https://doi.org/10.1097/00005344-200411000-00013

Topics

Heart failure HFrEF treatment HFpEF management

View Full Paper

Ask AI

Bookmark

Long-Term Treatment with a Phosphodiesterase Type 5 Inhibitor Improves Pulmonary Hypertension Secondary to Heart Failure through Enhancing the Natriuretic Peptides-cGMP Pathway

PICO

Discussion

Implication

Cite This Study

Topics

Long-Term Treatment with a Phosphodiesterase Type 5 Inhibitor Improves Pulmonary Hypertension Secondary to Heart Failure through Enhancing the Natriuretic Peptides-cGMP Pathway

PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider